The Indian weight-loss market reached a structural tipping point on March 20, when the patent on the blockbuster semaglutide expired. This regulatory opening unleashed an unprecedented wave of domestic manufacturing, allowing pharmaceutical giants to introduce generic alternatives at prices nearly 90% lower than original innovator brands. Suddenly, a therapy that was once the exclusive domain of affluent demographics became accessible to millions.
With this newfound affordability came an explosion of digital noise. Scrolling through Instagram feeds in late March reveals a dense thicket of polished graphics, smiling influencers, and seamless landing pages, all presenting the newest frontier in clinical wellness: the GLP-1 peptide pen.
Photo Credit: Instagram ad
While these digital banners resemble standard health-tech marketing, they have attracted the sharp attention of the Central Drugs Standard Control Organization (CDSCO). On March 10, the CDSCO issued a sweeping advisory reminding manufacturers and importers that advertising prescription drugs to the general public remains illegal under the Drugs and Cosmetics Act, 1940. The advisory clarifies that even surrogate forms of promotion—such as influencer collaborations and educational campaigns that subtly nudge consumers toward a specific pharmacological class—face strict regulatory scrutiny.
ALSO READ: Govt Intensifies Probe On GLP-1 Illegal Sales: Wholesalers, Online Platforms Under Radar
On March 24, the regulator went from issuing warnings to active, boots-on-the-ground enforcement. The Drugs Controller General of India (DCGI) coordinated a massive sweep across 49 entities, auditing wholesalers, retail pharmacies, and digital clinics. Notices were served to defaulters for improper prescription practices and unauthorised supply chain activity, signalling that the state is prepared to penalise those treating powerful metabolic modifiers as casual lifestyle accessories.
The 1954 Legal Trap
Startup platforms might assume these regulatory warnings apply only to legacy pharmaceutical manufacturers. Legal experts warn that the exposure extends much further into the consumer-facing tech ecosystem.
"While the advisory is addressed in terms to manufacturers, importers and marketing authorisation holders, the wider statutory prohibition is not confined to them," explains Karun Mehta, Partner at Khaitan & Co. He points to Section 3 of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, which prohibits advertisements relating to drugs for conditions specified in the Schedule to the Act, including diabetes and obesity. "On that footing, the exposure extends beyond manufacturers and importers to consumer-facing participants in a B2C model where they directly or indirectly promote or advertise a prescription drug to the public at large."
For wellness platforms operating in a business-to-consumer environment, this creates a formidable legal trap. While genuine medical literature and clinical protocols remain protected, any communication that builds commercial brand recall for a prescription medicine risks falling afoul of these decades-old laws.
"The law is not so wide as to eliminate every form of communication around these therapies; it preserves room for bona fide scientific or medical literature. Genuine medical literature, scientific exchange, and approved patient-use information may continue, so long as the communication remains within a legitimate informational or clinical setting and does not move into the realm of commercial promotion or consumer-facing information," Mehta says.
Photo Credit: Instagram ad
Brands Push Back: Education Or Promotion?
The platforms themselves view the situation differently, framing their campaigns as essential educational infrastructure for a complex medical market. Taniya Pandey, CMO of wellness giant VLCC, argues that their recent messaging was designed to curb the dangerous trend of self-medication.
"The headline 'Do you really need the needle?' is a question we genuinely wanted people to pause and ask themselves," Pandey notes. She emphasises that the initiative seeks to prevent unsupervised use by funneling patients through proper clinical diagnostics and doctor-led care. For VLCC, pharmacological intervention represents a single element within a comprehensive ecosystem of lifestyle management, dietary shifts, and behavioral therapy.
Mehta adds that the advisory "prohibits direct or indirect promotional activity addressed to the public, including surrogate forms such as disease-awareness campaigns, digital outreach, and similar communications where the effect is to promote a prescription product."
Photo Credit: Instagram ad
Digital wellness platform Healthify takes a similar stance, placing the focus on the nutritional and behavioral guardrails surrounding a patient's weight-management journey. The company clarifies that it does not manufacture or import medications, and its HealthifyRx and Patient Support Programs cater exclusively to individuals who have already secured a valid prescription from a registered medical specialist.
Photo Credit: Instagram ad
This creates a tense standoff between public health objectives and private sector outreach. While regulators demand an airtight separation between medical information and commercial promotion, wellness platforms argue that consumer-facing dialogue is the only way to steer desperate patients away from unsafe self-medication.
Multinational innovator brands appear to be playing it safe; Novo Nordisk declined to participate in advertisement-related discussions, citing the sensitivity of the CDSCO advisory. PharmEasy did not respond to queries for comment.
The March 20 patent expiry on semaglutide triggered an immediate price war across the Indian pharmaceutical sector. While innovator brands historically commanded premium pricing, domestic manufacturers have successfully crashed the entry barrier by up to 90%. Mehta adds that, "In the coming days, with the influx of such drugs, we are likely to see the regulator as well as the government keeping a close watch on stakeholders to ensure there is strict compliance and that consumer interest remains protected."
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.